Fig. 1From: Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutationsA detailed history of treatment and subsequent clinical outcomes of eight EGFR/ALK co-alternation patients are presented. The number in parentheses represent the PFS (Progression-free survival after EGFR-TKI treatment) for each drug, The arrow presents time point of EGFR/ALK co-alternation identificationBack to article page